Beberashvili Ilia, Ptashkin Ekaterina, Azar Ada, Hamad Ramzia Abu, Koren Shlomit, Stav Kobi, Efrati Shai
Nephrology Division, Assaf Harofeh Medical Center, Affiliated with the Sackler Faculty of Medicine Tel Aviv University, Zerifin, Israel.
Internal Department B, Assaf Harofeh Medical Center, Affiliated with the Sackler Faculty of Medicine, Tel Aviv University, Zerifin, Israel.
Clin Nutr. 2020 Oct;39(10):3199-3205. doi: 10.1016/j.clnu.2020.02.015. Epub 2020 Feb 15.
Obestatin, a physiological opponent of acylated ghrelin, is linked to appetite suppression regulation in mice but its anorexigenic properties in humans are controversial. We aimed to investigate obestatin's potential role in dietary intake regulation by examining response to a meal in maintenance hemodialysis (MHD) patients.
In this prospective observational case series study, we investigated the response of obestatin to a fixed calorie meal (500 kcal) in 21 MHD patients (age 69.2 ± 13.1 years, 10 women, with a body mass index 27.2 ± 5.5 kg/m). Parallel changes in serum obestatin and insulin levels and subjective scores of appetite (visual analogue scales for hunger, satiety, fullness and prospective food consumption) were recorded on fasting and 30, 60 and 120 min after the meal.
In a linear mixed effects model controlling for baseline demographics and clinical parameters including serum insulin concentrations, postprandial levels of obestatin did not change significantly from baseline in response to the meal. The response was the same in MHD patients treated with high- or low-flux dialyzers. However, postprandial obestatin levels were associated with the rate of change in sensation of fullness (linear estimate: 11.60 (95% confidence interval 0.17 to 23.04, P < 0.05)). The remaining sensations of appetite did not correlate with postprandial obestatin levels in time.
Obestatin levels do not change acutely with food administration in MHD patients, but associate with the changes in sensation of fullness. This supports the possible role of obestatin in the long-term regulation of appetite in MHD patients.
肥胖抑制素是酰基化胃饥饿素的生理拮抗剂,在小鼠中与食欲抑制调节有关,但其在人类中的厌食特性存在争议。我们旨在通过研究维持性血液透析(MHD)患者对进餐的反应,探讨肥胖抑制素在饮食摄入调节中的潜在作用。
在这项前瞻性观察性病例系列研究中,我们调查了21例MHD患者(年龄69.2±13.1岁,10名女性,体重指数27.2±5.5kg/m²)对固定热量餐(500千卡)的肥胖抑制素反应。记录空腹时以及餐后30、60和120分钟时血清肥胖抑制素和胰岛素水平的平行变化以及食欲的主观评分(饥饿、饱腹感、饱足感和预期食物摄入量的视觉模拟量表)。
在控制基线人口统计学和临床参数(包括血清胰岛素浓度)的线性混合效应模型中,餐后肥胖抑制素水平与基线相比无显著变化。使用高通量或低通量透析器治疗的MHD患者的反应相同。然而,餐后肥胖抑制素水平与饱足感的变化率相关(线性估计:11.60(95%置信区间0.17至23.04,P<0.05))。其余食欲感觉与餐后肥胖抑制素水平无时间相关性。
MHD患者进食后肥胖抑制素水平不会急性变化,但与饱足感的变化相关。这支持了肥胖抑制素在MHD患者食欲长期调节中的可能作用。